ESTRO 2024 - Abstract Book

S1371

Clinical - Head & neck

ESTRO 2024

and neck cancer after radiation therapy: Large-scale observational cohort. International Journal of Radiation Oncology*Biology*Physics, 111:549 – 558, 10 2021.

4. Aarup-Kristensen, C.R. Hansen, L. Forner, C. Brink, J.G. Eriksen, and J. Johansen. Osteoradionecrosis of the mandible after radiotherapy for head and neck cancer: risk factors and dose-volume correlations. Acta Oncologica, 58:1373 – 1377, 10 2019.

2032

Poster Discussion

Routinely collected ePROMs detect differences in HRQoL between patients with p16+ and p16- HNSCC

Isabella Fornacon-Wood 1,2 , Thitikorn Nuamek 2 , Kate Garcez 2 , Christopher Hughes 2 , Lip Wai Lee 2 , David Thomson 2,1 , Corinne Faivre-Finn 2,1 , Janelle Yorke 2,3 , James Price 2,1 1 The University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom. 2 The Christie NHS Foundation Trust, Department of Clinical Oncology, Manchester, United Kingdom. 3 The University of Manchester, Division of Nursing, Midwifery & Social Work, Manchester, United Kingdom

Purpose/Objective:

P16-positive oropharyngeal cancer, suggesting causation by high-risk human papillomavirus, is associated with high rates of survival and generally affects otherwise-well patients of working age. On the contrary, p16-negative head and neck squamous cell carcinoma (HNSCC), associated with tobacco and alcohol, is considered a distinct disease entity, and has a poorer prognosis. Electronic patient-reported outcome measures (ePROMs) have emerged as an effective tool to capture patients’ self -reported symptoms, treatment toxicities and health-related quality of life (HR QoL). This study aims to compare pre-radiotherapy HR-QoL from routinely collected ePROM questionnaires for patients with p16-positive and p16-negative HNSCC, with the hypothesis that patients with p16-negative HNSCC are more likely to report worse HR-QoL.

Material/Methods:

Patients with non-metastatic HNSCC were invited to complete ePROM questionnaires as part of their routine cancer care. In addition to symptom-related questions, questionnaires included the EuroQol EQ-5D-5L tool to assess HR QoL across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain is scored from 1 to 5 (1 – no problems within domain, 5 – extreme problems). Patients who completed pre radiotherapy ePROMs between February 2019 and July 2022 were included. Baseline patient demographic and clinical variables were collected via structured forms included in the patients’ electronic record. Patients were subdivided into p16-positive and p16-negative groups. Patients reporting problems within each HR-QoL domain (i.e., a score > 1) were compared to those without problems using the Chi-squared test and corrected for multiple comparisons using the Benjamini-Hochberg procedure. Univariable and multivariable ordinal regression was used to evaluate the association between p16 status and levels within each HR-QoL domain. Multivariable analyses were